Chronic lead poisoning treated with dimercaptosuccinic acid.
A 54-year-old male with chronic lead poisoning was treated with 2.3-dimercaptosuccinic acid (DMSA). A daily dosage of 30 mg/kg body weight for three days and 20 mg/kg for four days resulted in a decrease of the blood-lead concentration (B-Pb) from 3.7 to 0.7 mumol/l; the total amount of lead excreted in the urine during the first seven 24 hr periods was 75 mumol. After the treatment, B-Pb slowly increased to 3.3 mumol/l. A second treatment was then initiated and resulted in similar changes in B-Pb. However, during the third treatment, the patient developed a mucocutaneous vesicular flare; the eruptions faded after cessation of the chelation therapy, but could be provoked by DMSA doses of 10 mg/kg and above. Despite the small number of treatment courses, the patient showed obvious mental improvement and reported less headache and improved memory. Thus, DMSA is an efficient chelator that results in a rapid, though temporary decrease in B-Pb. Although oral treatment with this chelator may be supervised from the out-patient clinic, careful monitoring for potential side effects is recommended.
Grandjean
P
P
Institute of Community Health, Odense University, Denmark.
Jacobsen
I A
IA
Jørgensen
P J
PJ
D015913:Chelation Therapy; D002908:Chronic Disease; D006801:Humans; D007855:Lead Poisoning / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D009784:Occupational Diseases / Q000188:drug therapy*; D004113:Succimer / Q000627:therapeutic use*
D004113:Succimer